Keywords
carboxymethyl lysine - fluoride - sirtuin1 - therapeutics - type-2 diabetes mellitus
Introduction
Diabetes mellitus (DM) is a clinical syndrome characterized by unexplained weight
loss, polydipsia, polyuria, polyphagia, nonhealing or delayed healing of wounds, and
blurring of vision. The biochemical markers include fasting plasma glucose of ≥ 126 mg/dL
and postprandial plasma glucose of ≥ 140 mg/dL.[1] The World Health Organization (WHO) prediction states that by 2030, DM may be the
seventh leading cause of death worldwide.[2] Prevalence of DM is growing rapidly in Asian countries affecting low- and middle-income
groups.[3] Mathers and Loncar, in 2006, stated that approximately 328 million people will be
affected by DM, globally.[2] Studies conducted by Verma et al, in 2012, showed India as the capital for DM with
40.9 million diabetic patients.[4] An in-house study in 2010 demonstrated approximately 10% prevalence of diabetes
in local population.[5]
There are several factors influencing prevalence of DM such as heredity, environmental
factors, and lifestyle modifications. Among these factors, environmental factor and
lifestyle modifications are considered in this study. Environmental factor is described
as chronic fluoride exposure in the study area and study population as studied by
Verma et al.[6] Under lifestyle modifications, there are various aspects such as sedentary lifestyle,
unhealthy diet, improper knowledge regarding health checkup, and others, among which
unhealthy diet is considered as one of the risk factors in this study that is assessed
by serum carboxymethyl lysine (CML) levels.
CML is an advanced glycation end product (AGE) whose serum levels are mainly dependent
on dietary intake.[7] These factors increase oxidative stress in the body-generating reactive oxygen species
(ROS).[8] To combat the effects of fluoride and CML, either there must be antioxidants reserve
in body or continuous activation of oxidants scavenging mechanisms must happen.[9] There is need of a molecule which shall decrease and/or nullify the effects of both
CML and fluoride. The molecule identified is Sirtuin1 which is involved in longevity
guarding cells from aging preventing oxidative damage.[9] Sirtuin1, a nicotinamide adeninde dinucleotide (NAD)+-dependent deacetylase homologous
to silent information regulator 2 gene (Sir2) of Saccharomyces cerevisiae (Baker's yeast).[8]
[9] Ultimately, further molecular research on sirtuin1 may fetch details regarding its
exact pathways involved, resulting in therapeutic usage of sirtuin1 in aging disorder,
since it is considered as antiaging protein.
Diabetic nephropathy, a consequence of type-2 DM, is increasing across the nations
and higher in Asian Indians with a range of 30 to 40%, as reported in the year 2015,
can be due to environmental and genetic factors.[10] Since this study includes diabetic nephropathy, the association of CML and increased
rigidity of filtering apparatus are proved to be deteriorating renal health by many
human and animal studies.[11]
[12]
Since fluoride concentration is increasing day by day in drinking water of Kolar district,
along with incidence of type-2 DM and other aging disorders, this study was planned
as a preliminary trial. In this population, no studies have shown a correlation of
fluoride with insulin and diabetes. The framed hypothesis is fluoride and CML may
be an enhancer molecule of diabetes and sirtuin1 shall be the molecule for counter
action for fluoride toxicity. Estimation of sirtuin1 levels in blood may give a clue
to assess the damage by hyperglycemia collectively due to all kinds of causative factors
of type-2 DM. Sirtuin1 can be included as biomarker of aging and therapeutics in preventing
factors accelerating aging.
Materials and Methods
This is a comparative cross-sectional study with three groups.
Subjects
Type-2 diabetic patients attending outpatient department (OPD), department of general
medicine and diabetology, were recruited for the study after confirming inclusion
and exclusion criteria. All the patients were residents of Kolar district for minimum
of 3 years. Informed written consent was obtained from all study patients. Age- and
gender-matched nondiabetics and healthy patients of same area were included as controls.
Study Groups
Group I (n = 70): age and gender matched healthy controls living in Kolar as the patient of
the other groups.
Group II (n = 70): type-2 DM with diabetic nephropathy.
Group III (n = 70): type-2 DM diabetic nephropathy.
Inclusion Criteria
Patients clinically proven to be type-2 DM with or without diabetic nephropathy and
living and surviving in the same environment exposed to fluoride were included in
this study.
Exclusion Criteria
Exclusion criteria are as follows: (1) patients with DM not living in Kolar and not
exposed to fluoride, (2) patients taking drugs or other factors known to cause diabetes
and/or diabetic nephropathy, (3) patients undergoing any type of dialysis, (4) acute
kidney injury due to any cause and other renal pathologies, and (5) patients with
other type of diabetes. SPSS version 20 (IBM) was used to perform statistical analysis.
All the variables that are normally distributed (parametric), represented as mean ± standard
deviation (SD) and those which are nonparametric, represented as median (25th–75th
percentile). Analysis of variance (ANOVA) was used for calculating probability (p-value). Pearson's correlation (r) and spearman's correlation were used to find the trend between two variables of
normally and not normally distributed parameters, respectively. K-independent sample
test was used to derive the p-value of nonparametric data and considered Kruskal–Wallis test for calculation. The
chi-square test represents the significance of parameters between groups of not normally
distributed data. A p-value of < 0.05 was considered as statistically significant. Normal distribution
was assessed by considering Kolmogorov–Smirnov significance values.
Sample Collection
With all, strict aseptic precautions, making the patient lie in a comfortable position,
8-hour 4-mL fasting blood sample and 2-mL 2-hour postprandial blood sample was collected.
Fasting sample was split into parts with specified sample requirement as serum (plain
tubes), whole blood (HbA1c%), and plasma (ethylenediamine tetraacetic acid [EDTA])
for parameters as mentioned in measurement methods. Corresponding urine sample was
also collected from the study patients for urine fluoride analysis. Quality assurance
was performed as per the criteria laid down in the Clinical Diagnostic Laboratory
Services of college attached hospital facility and confirmed.
Methodology
All the routine investigations were performed by fully automated Vitro 5, 1 Fs, Vitros
(Ortho Clinical Diagnostics, United States), fasting insulin was analyzed by Vitro
eCI (Ortho Clinical Diagnostics, United States), and glycated hemoglobin was estimated
by BioRad D10 (California, United States) based on the principle of high performance
liquid chromatography (HPLC) at Biochemistry section of the Central Diagnostic Laboratory
Services facility at attached hospital. Manual methods were performed at department
of biochemistry of Sri Devaraj Urs Medical College. Blood pressure was measured before
fasting blood collection by mercury sphygmomanometer, height was measured by manual
stadiometer and, weight was recorded from digital weighing machine to calculate body
mass index (BMI) as kg/m2.
Sirtuin1, CML, and fructosamine were estimated by double antibody sandwich technique,
measured at λmax = 450 nm and expressed in ng/mL procured from Sincere biotech, China.[13]
[14]
[15] Cystatin C (Cys C) was, measured by newly designed Agappe mispa i2 nephelometry
based desktop instrument where intensity of the color is measured at λmax = 650 nm
expressed in mg/L.[16] Serum and urine fluoride was analyzed by Orion Thermo Scientific Fluoride Ion Selective
Electrode (ISE), United States. Readily available standards procured from thermo scientific
with total ionic strength–adjusting buffer (TISAB) were used for analysis. Then, 1,
2, and 10 ppm standards with TISAB II buffer were used for analyzing serum and urine
fluoride.
Very low density lipoprotein (VLDL) calculated by dividing triglyceride (TG) by 5:[17]
VLDL = TG / 5
Non–high density lipoprotein (nHDL) is now gaining importance against VLDL and HDL,
since it also has major role in assessing lipid accumulation in vascular diseases.[18]
non-HDL cholestrol = total cholesterol – HDL
Insulin resistance and sensitivity are calculated to get a glimpse of functioning
of target cells against secreted insulin. Based on homeostasis model assessment (HOMA)
and quantitative insulin-sensitivity check index (QUICKI) values, treatment and administration
of insulin dosage may be decided since they are calculated using fasting glucose and
insulin. In addition to diabetes, other disorders can also be staged by their values
such as, obesity, hyperlipidemia, polycystic ovarian disease, and others. Therefore
we considered to calculate HOMA–insulin resistance (IR)[19] and QUICKI by using the following formulae:
HOMA-IR: HOMA – IR = (fasting plasma insulin × fasting blood sugar) / 405
)[20]
QUICKI: QUICKI = 1 / [log (insulin [μU/mL]) + log (glucose [mg/dL])
All the calculations are done considering their limitations.
Results
Demographic data and diabetic profile are normally distributed and represented as
mean ± SD are tabulated in [Table 1]. Patients recruited for this study are age and gender matched and hence they are
not significant. Group 1 consisted of 31 (44.3%) male, group 2 contained 47 (67%)
male, and group 3 with 37 (52.8%) male patients of p-value of 0.08, indicating that gender-matched patients were recruited for all the
groups. In basic renal and lipid profile, all the parameters were significant across
groups except non-HDL which had a broad reference range.
Table 1
Demographic and biochemical parameters of all three groups
|
Parameter
|
Group 1 (n = 70)
|
Group 2 (n = 70)
|
Group 3 (n = 70)
|
p-Value
|
|
Demographic data
|
|
|
Age (y)
|
42.71 ± 9.2
|
56. 04 ± 8.2
|
53.1 ± 8.2
|
< 0.001
|
|
SBP (mm Hg)
|
122.1 ± 5.4
|
137.6 ± 17.6
|
125.3 ± 11.02
|
< 0.001
|
|
DBP (mm Hg)
|
78.3 ± 4.6
|
87.53 ± 11.2
|
82.23 ± 7.64
|
< 0.001
|
|
BMI (kg/m2)
|
24.1 ± 3.
|
22.6 ± 1.6
|
23.2 ± 1.83
|
< 0.001
|
|
Basic diabetic profile
|
|
|
FBS (mg/dL)
|
93.94 ± 9.4
|
173.6 ± 64.02
|
182.3 ± 67.7
|
< 0.001
|
|
PPBS (mg/dL)
|
115.1 ± 16.2
|
271.2 ± 91
|
273.1 ± 103
|
< 0.001
|
|
HbA1c (%)
|
5.5 ± 0.5
|
8.2 ± 2
|
9.2 ± 2.4
|
< 0.001
|
|
Basic renal profile
|
|
|
Blood urea (mg/dL)
|
19.6 ± 6.6
|
69.03 ± 27.5
|
27.6 ± 13.4
|
< 0.001
|
|
Serum creatinine (mg/dL)
|
0.66 ± 0.1
|
3.4 ± 1.5
|
0.68 ± 0.21
|
< 0.001
|
|
Uric acid (mg/dL)
|
4.4 (3.7–5.8)
|
4.0 (2.6–5.6)
|
4.0 (3.07–5.1)
|
0.023
|
|
Serum albumin (g/dL)
|
4.05 ± 0.4
|
2.8 ± 0.8
|
4.3 ± 0.9
|
< 0.001
|
|
Sodium (mEq/L)
|
137 ± 2.1
|
133.5 ± 5.1
|
135.8 ± 3.2
|
< 0.001
|
|
Potassium (mEq/L)
|
4.3 ± 0.41
|
4.6 ± 0.9
|
4.4 ± 0.5
|
0.016
|
|
Lipid profile
|
|
|
Total cholesterol (mg/dL)
|
171.4 ± 39.1
|
157.6 ± 59.6
|
183.3 ± 59.6
|
0.007
|
|
Triglycerides (mg/dL)
|
141 (93–193.5)
|
148 (114.5–211)
|
184 (119.5–215.5)
|
0.033
|
|
HDL (mg/dL)
|
39.3 ± 10.1
|
28.3 ± 10.3
|
40.9 ± 13.7
|
< 0.001
|
|
LDL (mg/dL)
|
98 (76.2–122)
|
87 (50.7–110.5)
|
104 (86.8–127.3)
|
0.01
|
|
VLDL (mg/dL)
|
28 (17.7–36.4)
|
30 (23–42.2)
|
36.9 (24–43.1)
|
0.020
|
|
nHDL (mg/dL)
|
132.1 ± 39.5
|
125.7 ± 58.9
|
145.4 ± 56.8
|
0.077
|
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting blood
sugar; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density
lipoprotein; nHDL, non–high density lipoprotein; PPBS, post- prandial blood sugar;
SBP, systolic blood pressure; VLDL, very low density lipoprotein.
Advanced biomarkers of diabetic nephropathy (DN) and fluorosis, namely, serum sirtuin1,
serum fluoride, urine fluoride, and CML are emphasized in [Table 2]. Advance biomarkers of DN and fluorosis have broad range of detection and were skewed
in distribution. The estimated variables in view of skewness were considered as nonparametric
and represented them as median (25th–75th percentile). Reference ranges for the parameters
are yet to be defined after population or multicentric study across the globe.
Table 2
Special parameters
|
Parameters
|
Group 1 (n = 70)
|
Group 2 (n = 70)
|
Group 3 (n = 70)
|
p-Value
|
|
Sirtuin1 (ng/mL)
|
46.76 (12.4–97)
|
34.74 (25.08–53.2)
|
49.6 (33.71–101.63)
|
0.002
|
|
Serum fluoride (ppm)
|
0.66 (0.62–0.72)
|
0.24 (0.2–0.5)
|
0.6 (0.56–0.68)
|
< 0.001
|
|
Urine fluoride (ppm)
|
0.89 (0.55–1.49)
|
0.24 (0.16–0.41)
|
0.72 (0.53–1.02)
|
< 0.001
|
|
CML (ng/mL)
|
899 (625.25–1,306.5)
|
1,815 (1,100–2,591.13)
|
1,870 (1,155.1–2,272.5)
|
< 0.001
|
Abbreviations: CML, carboxymethyl lysine; ppm, parts per million.
Due to broad range of values of short-term glycemic control, insulin estimation and
calculation of diabetes indices, these are considered as nonnormally distributed and
represented as median (25th–75th percentile). The results are shown in [Table 3]. Except fasting insulin, all the parameters showed a significant difference in their
values. Yet again, there is a vital increase in values of in group 3 but decrease
in QUICKI giving a concern to prevent diabetic complication in future.
Table 3
Extended diabetic profile
|
Parameters
|
Group 1 (n = 70)
|
Group 2 (n = 70)
|
Group 3 (n = 70)
|
p-Value
|
|
Fructosamine (ng/mL)
|
100.2 (55.8–172.4)
|
245.93 (0.16–0.41)
|
329.9 (131.42–88.2)
|
< 0.001
|
|
Insulin (μIU/mL)
|
9.9 (6.22–14.4)
|
8.82 (5.14–13.32)
|
9.11 (6.35–15.62)
|
0.370
|
|
HOMA-IR
|
2.34 (1.3–3.2)
|
3 (1.99–5.62)
|
4.35 (2.4–7.1)
|
< 0.001
|
|
QUICKI
|
0.34 ± 0.02
|
0.32 ± 0.03
|
0.3 (0.29–0.34)
|
< 0.001
|
Abbreviations: HOMA-IR, homeostasis model assessment–insulin resistance; QUICKI, quantitative
insulin check index.
To support the findings derived from our study, we analyzed Cys C and calculated estimated
glomerular filtration rate (eGFR) 2009 and 2012, considering both creatinine and creatinine
with Cys C, respectively. The values are documented in [Table 4].
Table 4
Extended renal profile
|
Parameters
|
Group 1 (n = 70)
|
Group 2 (n = 70)
|
Group 3 (n = 70)
|
p-Value
|
|
Cystatin C (mg/L)
|
0.9 (0.69–1.2)
|
4.3 (3–6.5)
|
2.3 (1.46–3.69)
|
< 0.001
|
|
eGFR (mL/min/1.73 m2)
|
|
|
CKD-EPI 2009[a]
|
109.5 (99–116.25)
|
26 (17.75–37.25)
|
106 (93–115.5)
|
< 0.001
|
|
CKD-EPI 2012[b]
|
92.5 (74–118.5)
|
60.5 (40–91)
|
118.5 (95.75–137.25)
|
< 0.001
|
Abbreviation: eGFR, estimated glomerular filtration rate; CKD-EPI, chronic kidney
disease-epidemiology.
a Equation based on creatinine.
b Equation based on creatinine and cystatin C.
Sirtuin1 is known to get fluctuated both physiologically and pathologically. This
made us to find the extent of fluctuation in comparison with serum CML and serum fluoride
for which we correlated using Spearman's rho correlation. The values are tabulated
in [Table 5].
Table 5
Correlation of serum fluoride and CML with sirtuin1
|
Parameters
|
Group 1 (n = 70)
|
Group 2 (n = 70)
|
Group 3 (n = 70)
|
|
Spearman's rho (ρ) correlation
|
|
Serum fluoride (ppm)
|
0.061
|
0.292
|
0.005
|
|
CML (ng/mL)
|
0.188
|
0.054
|
0.153
|
Abbreviations: CML, carboxymethyl lysine; ppm, parts per million.
To correlate the calculated values between groups 1 to 3 between HOMA-IR, QUICKI,
and sirtuin1, we applied Spearman's rho correlation tool. The values are depicted
in [Table 6].
Table 6
Correlation of HOMA-IR and QUICKI with sirtuin1
|
Parameters
|
Group 1 (n = 70)
|
Group 2 (n = 70)
|
Group 3 (n = 70)
|
|
Spearman's rho (ρ) correlation
|
|
HOMA-IR
|
0.028
|
+0.047
|
+0.073
|
|
QUICKI
|
+0.098
|
0.004
|
+0.022
|
Abbreviations: HOMA IR, homeostasis model assessment–insulin resistance; QUICKI, quantitative
insulin sensitivity check index.
Discussion
As already mentioned, oxidative stress, insulin resistance, and ecological imbalances
are the common reasons for metabolic disorder which must be battled by either inducing
or activating a cascade of processes which may mask disastrous activity in a system.
This study involves a very important dimension in metabolic disturbance, namely type-2
DM and fluorosis. Though fluoride is not the only important causative, fluoride shall
be considered one of the triggering factors or accelerators to end up in complication.
In the present study, [Table 1] represents the demographic details of all the study patients with control group
(group 1) consisting of 39 females and 31 males and DN group (group 2) with 23 females
and 47 males, indicating male gender is more affected with diabetic complication than
females. Group 3 (type-2 DM) patients consisted of 33 females and 37 males. The mean
age of the controls and cases were significantly different since onset of type-2 DM
and its complications are observed during the later stages of life, and hence the
mean age cases with DN (group 2) was 14 years more than group 1 (56. 04 ± 8.2 and
42.71 ± 9.2, respectively). Prevalence of diabetes by age is well represented in the
IDF Diabetes Atlas ninth edition that it increases gradually from younger age (20–24
years) to adults (44–62 years) to old age (64–79 years).[21] As far as BMI is considered, since the study was performed in a rural area and the
staple food being finger millets (ragi), a food with low glycemic index, most of the
patients' BMI was well within range, though there was some significant difference
in the mean values, especially between the controls (24.1 ± 3.14) and DN (22.6 ± 1.6)
due to restriction in diet.
Type-2 DM is diagnosed initially by fasting blood glucose (FBS) levels with more than
110 mg/dL are considered to be hyperglycemic according to WHO and American Diabetic
Association (ADA) which is found true in case of basic diabetic profile in current
study with FBS of groups 2 and 3 to be 173.6 ± 64.02 and 182.3 ± 67.7, respectively,
unlike the group 1 FBS (93.94 ± 9.4).[1]
[22] The cut-off range of glycated hemoglobin (HbA1c) by ADA to call it as diabetes is
≥ 6.5% which was satisfied by cases groups in this study with HbA1 values of DN and
type-2 DM to be 8.2 ± 2 and 9.2 ± 2.4, respectively.[22]
As a concluding remark, the basic tests performed proved to be confirmatory test to
classify patients as diabetic cases for this study. According to KDIGO 2020 guidelines,
chronic kidney disease (CKD) is defined as “persistent renal damage or albuminuria
for more than 3 months diagnosed by performing eGFR and/or urine albumin estimation”
or otherwise urine albumin by creatinine ration (UACR) is called as CKD.[23]
Current study is concentrated on the following essential parameters for renal function:
serum creatinine, blood urea, and serum albumin. Among the basic renal parameters
estimated, urea and creatinine (69.03 ± 27.5 and 3.4 ± 1.5 mg/dL, respectively) values
showed a sharp increase and albumin value (2.8 ± 0.8 mg/dL) was declined in group
2 which is a clear sign of renal function damage coinciding with the recommendations
of KDIGO 2020.[23]
Lipid profile test tabulated in [Table 1] and found that total cholesterol, HDL, LDL, VLDL, and nHDL were low in group 2 than
the other groups. There are many controversial studies on lipid levels in DN, Palazhy
and Viswanathan and Chen et al documented that lipid molecules are elevated in severe
DN cases.[24]
[25] On the other hand, group 3 (type-2 DM) patients showed dyslipidemia indicating disturbances
in lipid metabolism due to insulin resistance or poor diet control which, if continued,
may lead to comorbid conditions in accordance with Wu and Parhofer.[26]
Eventually, regular check on lipid profile in diabetes is mandatory to avoid further
complications. Special parameters considered in this study are, sirtuin1, CML, urine,
and serum fluoride. [Table 2] describes a decrease in sirtuin1, serum, and urine fluoride of group 2 (34.74 [25.08–53.2],
0.24 [0.2–0.5], and 0.24 [0.16–0.41]) compared with other groups. In a study conducted
by Gok et al in Turkey population, stated that sirtuin1 can be a potential biomarker
in type-2 DM diagnosis along with microRNA 181a and 132 which affects sirtuin1 physiological
activity.[27] Serum fluoride levels are high in groups 1 and 3 (0.66 [0.62–0.72] and 0.6 [0.56–0.68])
and, likewise, its excretion is also proportionate (0.89 [0.55–1.49] and 0.72 [0.53–1.02])
unlike group 2 whose serum and urine fluoride levels (0.24 [0.2–0.5] and 0.24 [0.16-
0.41]) are equal, which means renal clearance is decreased. From the total fluoride
ingested, in children, 80% is absorbed by mineralized tissues and 30 to 50% is absorbed
in young and middle-aged people.[28] Unabsorbed fluoride is mainly excreted through urine in a healthy person.[28]
During renal damage, fluoride excretion is hindered leading to increased serum fluoride
and complications as evident from this study. In an animal study by Suzuki and Bartlett,
increase in sirtuin1 acted as a protective molecule against fluoride damage by activating
autophagy which gives a new hypothesis to be applied in human biology.[29] Similarly, CML values were almost equal in group 2 (1,815 [1,100–2,591.13]) compared
with group 3 (1,870 [1,155.1–2,272.5]) but is decreased in group 1 (899 [625.25–1,306.5]).
As described by Hammes et al in 1999, CML influences on renal function in maintaining
AGE homeostasis, and CML is usually found increased in diabetes and its complications
especially in DN, and hence the finding in this study is evident of the same.[30] Although, the urinary CML excretion is uncertain and not much associated with intake
and the status of the individual's metabolism.[31] To summarize, increased CML and fluoride act as prooxidant, restricting the effect
of sirtuin1 on cellular damage causing further complication, such as increased insulin
resistance and decreased insulin sensitivity, which is in line with the findings of
Uribarri et al.[14]
Extended diabetic and renal profile were included to assess in-depth consequences
of fluoride and CML (type-2 DM) in prognosis of disorder. Analogous to HbA1c glycated
albumin (fructosamine) is considered to be short-term (2–3 weeks of half-life) indicator
of protein glycation, an upcoming parameter of interest, its increase is directly
proportional to blood glucose.[15] Nevertheless, Cohen et al documented that HbA1c and fructosamine have glycosylation
gap but are good predictor of average glucose of long- and short-term controls which
is proven right from this study from [Table 3]. There is an increased fructosamine level in group 2 (245.93 [0.16–0.41]) and group
3 (329.9 [131.42–88.2]) when compared with group 1.[32] Since fructosamine levels are dependent on serum albumin concentration and eventually
the serum albumin is decreased in DN, there is a fall in fructosamine concentration
in DN than in type-2 DM. Fasting insulin was analyzed to calculate HOMA-IR and QUICKI.
Insulin values were decreased in DN and high in type-2 DM; there is no much significance
in insulin values since it has a broad reference range. As we move down the table,
HOMA-IR was calculated using online calculator with the formula derived by Matthews
et al.[19] HOMA-IR value of ≥ 3.5 is considered as insulin resistance as per IDF.[33] QUICKI value of < 0.32 indicates diabetes with decreasing insulin sensitivity concordant
with values of Chen et al. Therefore, it is evident from previous studies and current
study that HOMA-IR and QUICKI can act as better surrogate markers of insulin action
in diagnosis of diabetes.
Serum creatinine is considered the gold-standard marker for diagnosis of renal impairment;
however, due to least specificity and other dependent factors, there was a need for
more specific biomarker and hence emerged Cys C which is found high in serum during
renal insufficiency and specific to renal function. From [Table 4], the values of serum Cys C were high in group 2 patients (4.3 [3–6.5]) than in other
groups which is in agreement with study by Jeon et al.[34] This study employed eGFR equations by creatinine and a combination of creatinine
and Cys C in which group 2 showed a decline in both the equations of eGFR (26 [17.75–37.25]
and 60.5 [40–91], respectively), confirming the deterioration of renal function.
Moving across the table, eGFR of groups 1 and 3 was within normal range and were not
significant between both for eGFR creatinine values unlike the creatinine and Cys
C values which was less in group 1 (92.5 [74–118.5]) than group 3 (118.5 [95.75–137.25])
being significant in comparison with controls may be because of some outlier of Cys
C values. Hence, concluding remark regarding eGFR, eGFR Eq. 2009 is a better indicator
and serum Cys C alone is a better surrogate marker than creatinine in diagnosis of
DN.
In the present study, the vital parameters, such as CML, fluoride, sirtuin1, Cys C,
and insulin resistance and sensitivity, were compared conclude the study findings.
[Table 5] serum fluoride, CML, and Cys C with sirtuin1 found that serum fluoride and CML,
which are the causative molecules for worsening the disease progression, were found
negatively correlated in all the groups, indicating the activation of sirtuin1 action
on cells under damage. CML decrease during increased sirtuin1 indicates deacetylation
of the protein suppression, as demonstrated by Uribarri et al.[14] Similarly, increased sirtuin1 protects cells from fluoride induced stress by activating
autophagy, as demonstrated by Suzuki and Bartlett in an animal study.[29]
Other important component of this study is insulin action (insulin resistance [IR]
and insulin sensitivity [IS]) derived by HOMA-IR and QUICKI calculation. Comparison
of insulin sensitivity and resistance with insulin resistance may indirectly indicate
the cellular status in insulin reception. From [Table 6], negative correlation indicates decrease in HOMA-IR values, indicating decreased
resistance during increased sirtuin1 values and vice versa in regard with QUICKI,
since increased QUICKI value in general means increased sensitivity. Therefore, correlation
outcome of this study clearly indicates that though there is no significant correlation,
the trend is an evidence for curative nature of sirtuin1 in insulin sensing of cells
for glucose metabolism not only in DM but also in other insulin-related disorders
such as metabolic syndrome, obesity, thyroidism, and others. Uribarri et al correlated
CML as contributor to increased IR and suppression of these shall help activating
sirtuin1 protective mechanism and revert the changes to normal which gives a lead
to conclude this study.[14]
The present study is conducted in fluoride endemic area and recruited type-2 DM and
DN cases, a correlation of fluoride exposure and excretion with eGFR were correlated
in a three-dimensional graph for groups 1 to 3 (triple axis). Group 1 (controls) showed
a better positive correlation indicating a normal functioning renal apparatus represented
in [Fig. 1]. [Fig. 2] represented a strong inverse correlation indicating decline in renal function in
group 2 (diabetic nephropathy). A poor positive correlation was observed in group
3 [Fig. 3], conclusive that there may be a strong possibility of diabetic complication, especially
renal impairment at the earliest.
Fig. 1 Correlation of serum and urine fluoride with eGFR in group 1 (healthy controls).
G1SF, group 1 serum fluoride; G1UF, group 1 urine fluoride; G1eGFR, group 1 estimated
glomerular filtration rate.
Fig. 2 Correlation of serum and urine fluoride with eGFR in group 2 (diabetic nephropathy).
G2SF, group 2 serum fluoride; G2UF, group 2 urine fluoride; G2eGFR, group 2 estimated
glomerular filtration rate.
Fig. 3 Correlation of serum and urine fluoride with eGFR in group 3 (type-2 DM). DM, diabetes
mellitus; G3SF, group 3 serum fluoride; G3UF, group 3 urine fluoride; G3eGFR, group
3 estimated glomerular filtration rate.
Conclusion
From the present study, it is comprehensible that fluoride and diabetes in combination
is a fast destructing disorder of normal metabolism. Since fluorosis and diabetes
are globally prevailing epidemiological hitch, there is a need of a biomarker and/or
a therapeutic molecule to trace or heal the consequences. The prime molecule of interest
in this study is sirtuin1 that is now gaining momentum in the era of aging disorders,
hence it is included in this study to find its trend in diabetes and fluorosis.
The alterations in serum sirtuin1 levels indicate the severity of damage due to stress
during hyperglycemia and toxicity in fluorosis, hence sirtuin1 can be considered a
biomarker of aging. Subsequently, the correlation of CML, eGFR, and fluoride with
sirtuin1 indicates that increasing sirtuin1 may defend the forthcoming damage, hence
could be considered in therapeutics. It is clear that fluoride and CML can alter sirtuin1
values, therefore decrease in sirtuin1 value is a consequence of hyperglycemia and
fluorosis. To certain extent of injury, sirtuin1 synthesis will be triggered, beyond
which the inability will persist due to loss of normal cell function.
We could document that fluoride and CML alter sirtuin1 values. Decrease in sirtuin1
value is a consequence of uncontrolled hyperglycemia and chronic fluorosis in DN.
The levels of sirtuin1 are directly proportional to its synthesis in DM and inversely
proportional in DN.
To substantiate our findings and before giving a status to the molecules, sirtuin1
and fluoride, we propose in vitro studies by using cell lines and to decide on therapeutic
applications of sirtuin1. Further in vitro studies and studies comparing the nutrition
intake may help find the actual point of action of molecules to find remedies to fight
against aging and its effects.
